Statistics from Altmetric.com
Systemic sclerosis (SSc) is a connective tissue disease affecting various organs including the peripheral vessels and resulting in Raynaud`s phenomenon. For treatment of Raynaud's phenomenon, the vasodilator Prostaglandin I2 analogue iloprost is widely used. Fluorescence optical imaging (FOI) is an in vivo technique to visualise inflammation based on the accumulation of fluorescence optical contrast media (indocyanine green, ICG) which is proved in patients with rheumatoid arthritis.1 The aim of this prospective pilot-study was to visualise inflammation before and after treatment with iloprost using FOI in patients with SSc and associated Raynaud`s phenomenon (figure 1).
Contributors Study design: AP, PO and KD. Data collection: AP, KD and CJ. Image interpretation: AP, KD and JB. Statistical analysis: AP and JB. Manuscript writing: AP and GW. Manuscript editing: PO and GW.
Funding The project received a grant from Bayer Vital GmbH in December 2013.
Competing interests None.
Patient consent Obtained.
Ethics approval Ethics Committee of Friedrich-Schiller-University Jena.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.